You can use this page to generate a bio about me to suit your needs.
If you're going to read it out, please to generate a short version.
A recent CV is available: matthew-might-cv.pdf.
A recent NIH biosketch is available here.
Please contact me if you need a newer version of any of this material.
Check or uncheck these to modify the bio:Use formal titles?
INTRONAME has been the Director of the Hugh Kaul Precision Medicine Institute at the University of Alabama at Birmingham (UAB) since 2017. At UAB, NEXTNAME is the Hugh Kaul Endowed Chair of Personalized Medicine, a Professor of Internal Medicine and a Professor of Computer Science. At UAB, NEXTNAME's NIH and philanthropically funded research focuses on precision prevention, diagnosis and therapeutics using genomics, model systems, drug screens and artificial intelligence. A principal theme in his research is the use of computer and data science to enhance clinical and academic medicine.
From 2016 to 2018, NEXTNAME was a Strategist in the Executive Office of the President in The White House. At The White House, NEXTNAME worked primarily on President Obama's Precision Medicine Initiative with both the NIH and the Department of Veterans Affairs. In 2015, NEXTNAME joined the faculty of the Department of Biomedical Informatics at the Harvard Medical School, first as Visiting Professor and since 2017 as Senior Lecturer. At Harvard, NEXTNAME's research focuses on rare disease discovery and diagnosis, and on the development of personalized therapeutics.
NEXTNAME's journey from computer science to medicine has been inspired by his son Bertrand. In 2012, Bertrand was the first patient in the world to be diagnosed with NGLY1 deficiency, and this inspired NEXTNAME to use social media to discover other patients and form a community. Through the community's efforts in science, two therapeutics for NGLY1 deficiency have been identified since its discovery, and more are under active development. At present, NEXTNAME is an investigator on two NIH-supported projects to develop and trial targeted therapeutics for NGLY1 deficiency. NEXTNAME is co-founder and Chief Scientific Officer of NGLY1.org, a non-profit dedicated to finding treatments for NGLY1 deficiency, and he was a co-founder and Scientific Advisor to Pairnomix, a start-up which identifies potential patient-specific therapies for rare disorders -- and genetic epilepsies in particular. Q State Biosciences acquired Pairnomix in October 2018 and NEXTNAME remains a Scientific Advisor and Board Member.
Prior to medicine, NEXTNAME spent nearly a decade as a professor of computer science at the University of Utah. In computer science, NEXTNAME's research focuses primarily on cybersecurityautomated detection of security vulnerabilities; scientific computingdomain-specific languages for scientific computing; and automated reasoning about programsstatic analysis of higher-order programs. His research has also included excursions into parsing (with derivatives) and purely functional algorithms and data structures. At Utah, his research was supported by the Department of Defense (via DARPA), the Department of Energy and the National Science Foundation, including an NSF CAREER Award in 2014. In 2014, he was named one of University of Utah's first six Presidential Scholars.
NEXTNAME received his B.S. (2001), M.S. (2005) and Ph.D. (2007) in computer science from Georgia Tech.